{
  "docId": "019dd923-622c-750b-8b99-62a16d2a2f71",
  "docSlug": "747988e81365",
  "documentTitle": "Hims & Hers Health, Inc. (HIMS)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-07-13 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 59,
  "pageCount": 105,
  "prevPage": 58,
  "nextPage": 60,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses screenshots of actual FDA Form 483 inspection reports to substantiate the claims.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "screenshot",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-62a16d2a2f71/59",
  "deckHref": "/decks/019dd923-622c-750b-8b99-62a16d2a2f71",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-62a16d2a2f71.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-62a16d2a2f71#slide-59",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We find that FDA inspections of Curexa in 2022 and 2020 uncovered sloppy operations, below-strength products, and even facility structural concerns.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0f1d-76e6-8707-7a878bec57b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "image",
      "text": "FDA 2020 Inspection Report Excerpt",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57668cbb-1f55-4aae-91f2-61868d2f16fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "image",
      "text": "FDA 2022 Inspection Report Excerpt",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce5d59ce-e10f-4070-b625-c85f0a2bdf8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.75,
        "x": 0.2,
        "y": 0.35
      },
      "kind": "list",
      "text": "Observation 1: Non-microbial contamination. Observation 2: Hazardous drugs/cross-contamination. Observation 3: Sub-standard product strength/purity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bad1495-8d39-4711-9c5d-8c539bed6f7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Curexa (incorporated as EHT Pharmacy and now as Curexa – East II, LLC) is a small family-owned pharmacy that provides compounding and pharmacy services for telehealth companies and medical providers. We find that FDA inspections of Curexa facilities in 2022 and 2020 uncovered sloppy operations, below-strength products, and even facility structural concerns.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bb6368f-056f-4c94-9f93-492034a38801",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: FDA 2022 Inspection Report, FDA 2020 Inspection Report, Spruce Point red underline emphasis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab8e0ae2-f13d-4e4a-ad72-acbe91345741",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Curexa Has Received Three Inspection Letters From The FDA Since 2018 Detailing Deficient Practices And Products Produced",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d79a4ff1-d856-4d02-8138-1eb0373f5820",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "614d3553-1f79-4ab1-8941-cea8b9e74d13",
      "evidence": "Exposing operational deficiencies and regulatory non-compliance to undermine company credibility.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 105,
      "from": 15,
      "beatId": "e37982bf-a669-4ff0-9d59-9ad104610c60",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Expose Contradiction",
      "beatSlug": null,
      "evidence": "The document presents numerous contradictions and issues with HIMS' business model, operations, and financials",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}